273 related articles for article (PubMed ID: 25827165)
1. Antidiabetic agents and endothelial dysfunction - beyond glucose control.
Eriksson L; Nyström T
Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):15-25. PubMed ID: 25827165
[TBL] [Abstract][Full Text] [Related]
2. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
Kitasato L; Tojo T; Hatakeyama Y; Kameda R; Hashikata T; Yamaoka-Tojo M
Cardiovasc Diabetol; 2012 Jun; 11():79. PubMed ID: 22748110
[TBL] [Abstract][Full Text] [Related]
3. Changes in serum adiponectin concentrations and endothelial function after intensive insulin treatment in people with newly diagnosed type 2 diabetes: a pilot study.
Li F; Zhao T; Wen X
Diabetes Res Clin Pract; 2011 Nov; 94(2):186-92. PubMed ID: 21871685
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
Otsuki M; Goya K; Kasayama S
Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes.
Cariou B
Diabetes Metab; 2012 Oct; 38(4):298-308. PubMed ID: 22672960
[TBL] [Abstract][Full Text] [Related]
6. Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus.
Swidan SZ; Montgomery PA
Pharmacotherapy; 1998; 18(5):961-72. PubMed ID: 9758308
[TBL] [Abstract][Full Text] [Related]
7. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies.
Kaur R; Kaur M; Singh J
Cardiovasc Diabetol; 2018 Aug; 17(1):121. PubMed ID: 30170601
[TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
Bajaj M; Jialal I
Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
[No Abstract] [Full Text] [Related]
9. Drug treatments to restore vascular function and diabesity.
Cardillo C
Ann Pharm Fr; 2013 Jan; 71(1):27-33. PubMed ID: 23348853
[TBL] [Abstract][Full Text] [Related]
10. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
11. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Wilding JP
Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
[TBL] [Abstract][Full Text] [Related]
12. Effect of gender on prognosis in patients with myocardial infarction and type 2 diabetes.
Venskutonyte L; Malmberg K; Norhammar A; Wedel H; Rydén L
J Intern Med; 2010 Jul; 268(1):75-82. PubMed ID: 20210844
[TBL] [Abstract][Full Text] [Related]
13. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Nyström T; Gutniak MK; Zhang Q; Zhang F; Holst JJ; Ahrén B; Sjöholm A
Am J Physiol Endocrinol Metab; 2004 Dec; 287(6):E1209-15. PubMed ID: 15353407
[TBL] [Abstract][Full Text] [Related]
14. Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents.
Dandona P; Aljada A
J Diabetes Complications; 2004; 18(2):91-102. PubMed ID: 15120703
[TBL] [Abstract][Full Text] [Related]
15. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
16. Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics.
Ceriello A; Esposito K; Ihnat M; Thorpe J; Giugliano D
Diabet Med; 2010 Aug; 27(8):911-7. PubMed ID: 20653749
[TBL] [Abstract][Full Text] [Related]
17. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus.
Guerci B; Böhme P; Kearney-Schwartz A; Zannad F; Drouin P
Diabetes Metab; 2001 Sep; 27(4 Pt 1):436-47. PubMed ID: 11547217
[TBL] [Abstract][Full Text] [Related]
18. Metformin: effects on micro and macrovascular complications in type 2 diabetes.
Bailey CJ
Cardiovasc Drugs Ther; 2008 Jun; 22(3):215-24. PubMed ID: 18288595
[TBL] [Abstract][Full Text] [Related]
19. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.
Hopkins ND; Cuthbertson DJ; Kemp GJ; Pugh C; Green DJ; Cable NT; Jones H
Diabetes Obes Metab; 2013 Aug; 15(8):770-3. PubMed ID: 23451821
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes among women: clinical considerations for pharmacological management to achieve glycemic control and reduce cardiovascular risk.
Levine JP
J Womens Health (Larchmt); 2008 Mar; 17(2):249-60. PubMed ID: 18321176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
